Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes

Bibliography

• Gerstein HC, Miller ME, Byington RP, Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2011. Diabetes Care 2011;34(Suppl 1):S11-61
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
   PubMed Web of Science ®Google Scholar
• Kennedy AG, MacLean CD, Littenberg B, The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care 2005;28:1029-34
   PubMed Web of Science ®Google Scholar
• Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416-22
   PubMed Web of Science ®Google Scholar
• Zieve FJ, Kalin MF, Schwartz SL, Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83
   PubMed Web of Science ®Google Scholar
• Suzuki T, Oba K, Igari Y, Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study. J Diabetes Complications 2012; published online 10 January 2012; doi:10.1016/j.jdiacomp.2011.11.008
   Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74
   PubMed Web of Science ®Google Scholar
• Staels B, Handelsman Y, Fonseca V. Bile acid sequestrants for lipid and glucose control. Curr Diab Rep 2010;10:70-7
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64
   PubMed Web of Science ®Google Scholar
• Davidson MH, Dillon MA, Gordon B, Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-900
   PubMed Web of Science ®Google Scholar
• Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008;168:1975-83
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Rosenstock J, Wang AC, Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-84
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-40
   PubMed Web of Science ®Google Scholar
• Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003;72:137-74
   PubMed Web of Science ®Google Scholar
• Goodwin B, Jones SA, Price RR, A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000;6:517-26
   PubMed Web of Science ®Google Scholar
• Li T, Chiang JY. Bile acid signaling in liver metabolism and diseases. J Lipids 2012; published online 3 October 2011; doi:10.1155/2012/754067
   Google Scholar
• Inagaki T, Choi M, Moschetta A, Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217-25
   PubMed Web of Science ®Google Scholar
• Beysen C, Murphy EJ, Deines K, Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 2012;55:432-42
   PubMed Web of Science ®Google Scholar
• Brufau G, Stellaard F, Prado K, Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010;52:1455-64
   PubMed Web of Science ®Google Scholar
• Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006;99:257-73
   PubMed Web of Science ®Google Scholar
• Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab Syndr Relat Disord 2009;7:255-8
   PubMedGoogle Scholar
• Rigby SP, Handelsman Y, Lai YL, Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract 2010;16:53-63
   PubMed Web of Science ®Google Scholar
• Steinmetz KL. Colesevelam hydrochloride. Am J Health Syst Pharm 2002;59:932-9
   PubMed Web of Science ®Google Scholar
• Herrema H, Meissner M, van Dijk TH, Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice. Hepatology 2010;51:806-16
   PubMed Web of Science ®Google Scholar
• Yang ZX, Shen W, Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol Int 2010;4:741-8
   PubMed Web of Science ®Google Scholar
• Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 2001;35:898-907
   PubMed Web of Science ®Google Scholar
• Brunetti L, Hermes-Desantis ER. The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus. Ann Pharmacother 2010;44:1196-206
   PubMed Web of Science ®Google Scholar
• Daily Med: WELCHOL (colesevelam hydrochloride) tablet, film coated; WELCHOL (colesevelam hydrochloride) for suspension. Daiichi Sankyo, Inc. Bethesda, MD: U.S. National Library of Medicine, 2011. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a06d3b2-7229-4398-baba-5d0a72f63821 [Last accessed 7 December 2011]
   Google Scholar
• Corsini A, Windler E, Farnier M. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur J Cardiovasc Prev Rehabil 2009;16:1-9
   PubMed Web of Science ®Google Scholar
• Insull W Jr, Toth P, Mullican W, Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001;76:971-8232
   PubMed Web of Science ®Google Scholar
• Heller DP, Burke SK, Davidson DM, Donovan JM. Absorption of colesevelam hydrochloride in healthy volunteers. Ann Pharmacother 2002;36:398-403
   PubMed Web of Science ®Google Scholar
• Rosenbaum DP, Petersen JS, Ducharme S, Absorption, distribution and excretion of GT31-104, a novel bile acid sequestrant, in rats and dogs after acute and subchronic administration. J Pharm Sci 1997;86:591-5
   PubMed Web of Science ®Google Scholar
• Weitzman SP, Ginsburg KC, Carlson HE. Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine. Thyroid 2009;19:77-9
   PubMed Web of Science ®Google Scholar
• Brown KS, Armstrong IC, Wang A, Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. J Clin Pharmacol 2010;50:554-65
   PubMed Web of Science ®Google Scholar
• Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet 2004;43:943-50
   PubMed Web of Science ®Google Scholar
• Donovan JM, Kisicki JC, Stiles MR, Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother 2002;36:392-7
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr Med Res Opin 2008;24:995-1009
   PubMed Web of Science ®Google Scholar
• Moore A, Phan BA, Challendar C, Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. J Clin Lipidol 2007;1:620-5
   PubMed Web of Science ®Google Scholar
• Daily Med: ZETIA (ezetimibe) tablet. MSP Distribution Services © LLC. Bethesda, MD: U.S. National Library of Medicine, 2012. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a773b0b2-d31c-4ff4-b9e8-1eb2d3a4d62a [Last accessed 15 February 2012]
   Google Scholar
• Daily Med: NIASPAN ER (niacin) tablet, film coated, extended release. Lake Erie Medical DBA Quality Care Products LLC. Bethesda, MD: U.S. National Library of Medicine, 2011. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0dfe662a-f2ac-4f10-9a08-54cbd0c6dec6 [Last accessed 15 February 2012]
   Google Scholar
• Donovan JM, Stypinski D, Stiles MR, Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000;14:681-90
   PubMed Web of Science ®Google Scholar
• Walker JR, Brown K, Rohatagi S, Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colesevelam (Welchol). J Clin Pharmacol 2009;49:1185-95
   PubMed Web of Science ®Google Scholar
• Hanus M, Zhorov E. Bile acid salt binding with colesevelam HCl is not affected by suspension in common beverages. J Pharm Sci 2006;95:2751-9
   PubMed Web of Science ®Google Scholar
• Goldfine AB, Fonseca VA, Jones MR, Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes. Horm Metab Res 2010;42:23-30
   PubMed Web of Science ®Google Scholar
• Stein EA, Marais AD, Szamosi T, Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr 2010;156:231-6
   PubMed Web of Science ®Google Scholar
• Ovalle F, Philis-Tsimikas A, Truitt K, Colesevelam HCl improves glycemic control, independent of age, in patients with type 2 diabetes uncontrolled on metformin, sulfonylurea, or insulin-based therapy. Diabetes 2007;56(Suppl 1):A536
   Google Scholar
• Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis 2009;204:342-4
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64
   PubMed Web of Science ®Google Scholar
• Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol 2011;26:342-7
   PubMed Web of Science ®Google Scholar
• Rajpathak SN, Kumbhani DJ, Crandall J, Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924-9
   PubMed Web of Science ®Google Scholar
• Baker WL, Talati R, White CM, Coleman CI. Differing effects of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98-107
   PubMed Web of Science ®Google Scholar
• Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002;90(Suppl 2):50-60
   Google Scholar
• Robinson DM, Keating GM. Colesevelam: a review of its use in hypercholesterolemia. Am J Cardiovasc Drugs 2007;7:453-65
   PubMed Web of Science ®Google Scholar
• Henry RR, Aroda VR, Mudaliar S, Effects of Colesevelam on Glucose Absorption and Hepatic/Peripheral Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus. Diabetes Obes Metab 2012;14:40-6
   PubMed Web of Science ®Google Scholar
• Schwartz SL, Lai YL, Xu J, The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord 2010;8:179-88
   PubMed Web of Science ®Google Scholar
• Suzuki T, Oba K, Igari Y, Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nihon Med Sch 2007;74:338-43
   PubMedGoogle Scholar
• Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005;329:386-90
   PubMed Web of Science ®Google Scholar
• Chen L, McNulty J, Anderson D, Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. J Pharmacol Exp Ther 2010;334:164-70
   PubMed Web of Science ®Google Scholar
• Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009;8:369-85
   PubMed Web of Science ®Google Scholar
• Hofmann AF. Bile acid sequestrants improve glycemic control in type 2 diabetes: a proposed mechanism implicating glucagon-like peptide 1 release. Hepatology 2011;53:1784
   PubMed Web of Science ®Google Scholar
• Goldfine AB. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Curr Opin Cardiol 2008;23:502-11
   PubMed Web of Science ®Google Scholar
• Patti M-E, Houten SM, Bianco AC, Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 2009;17:1671-7
   PubMed Web of Science ®Google Scholar
• Kir S, Beddow SA, Samuel VT, FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011;331:1621-4
   PubMed Web of Science ®Google Scholar
• Fu L, John LM, Adams SH, Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004;145:2594-603
   PubMed Web of Science ®Google Scholar
• Li T, Owsley E, Matozel M, Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 2010;52:678-90
   PubMed Web of Science ®Google Scholar
• Li T, Francl JM, Boehme S, Glucose and insulin induction of bile acid synthesis: mechanisms and implications in diabetes and obesity. J Biol Chem 2012;287:1861-73
   PubMed Web of Science ®Google Scholar
• Garg SK, Ritchie PJ, Moser EG, Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. Diabetes Obes Metab 2011;13:137-43
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Goldberg RB, Garvey WT, Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract 2010;16:617-28
   PubMedGoogle Scholar
• Vega GL, Dunn FL, Grundy SM. Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. Am J Cardiol 2011;108:1129-35
   PubMedGoogle Scholar
• Rosenstock J, Fonseca VA, Garvey WT, Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract 2010;16:629-40
   PubMed Web of Science ®Google Scholar